Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Modivcare Establishes Transportation Provider Advisory Council to Capture Voice of Community-Based Transportation Providers

Modivcare

Modivcare Inc. (“Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions, announced today that it has established a national Transportation Provider Advisory Council (TPAC) to gather feedback and perspective from representatives of its network of 5,500 transportation providers. National in scope, the TPAC includes members from each major region of the U.S. While out-of-network transportation providers may be consulted on occasion, the TPAC will generally consist of contracted in-network providers of any size who enthusiastically share with Modivcare candid feedback, improvements, innovations, and forward-looking recommendations. In addition to helping Modivcare develop a deeper understanding of customer perspectives and experiences, the TPAC enables Modivcare to obtain transportation provider input in establishing new innovative services, while also improving existing services and processes. The TPAC will meet on a quarterly basis and be led by a designated Modivcare council chair and assistant chair. “Modivcare is deeply committed to developing strong, productive relationships within our nationwide network of community-based transportation providers, so that we can create a greater sense of partnership between us, and in turn, a consistent patient experience,” said Dan Greenleaf, President and CEO of Modivcare. “We are proud to announce the establishment of our Transportation Provider Advisory Council, which will provide valuable, actionable information that will improve our ability to support our customers.” “I am honored and take with great responsibility being asked to participate on this council,” said David Cason, President and CEO of New Mexico-based Shuttle Ruidoso, a TPAC member. “I was recently elected to lead a coalition of approximately 35 other transportation providers, and I hope to bring to the council not only the single voice of Shuttle Ruidoso but also a shared voice of all the providers in our state's network.” “As an NEMT provider, the most important factor in our business is having empathy for our customers. It is our foundation,” said Brisa Berumen-Dixon, CEO of Illinois-based Seabreeze Non-Emergency Medical Transportation, a TPAC member. “I am proud to join the council to share our employees’ and customers’ experiences with Modivcare as we work towards the shared goal of breaking down health-equity barriers.” Modivcare’s non-emergency medical transportation (NEMT) services provide patients access to safe and reliable rides to health services. Working with local, community-based transportation providers, Modivcare is the largest broker of NEMT in the nation and brings more than 35 years of experience to its transportation providers and more than 75 million trips managed annually for 30 million patients across the United States. # # # # About Modivcare Modivcare Inc. (“Modivcare”) (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal and home care, remote patient monitoring, medication management and meal delivery. Modivcare also holds a minority equity interest in CCHN Group Holdings, Inc. and its subsidiaries (“Matrix Medical Network”), which partners with leading health plans and providers nationally, delivering a broad array of assessment and care management services to individuals that improve health outcomes and health plan financial performance. To learn more about Modivcare, please visit www.modivcare.com. Contact Details Kate Zerone Director, Ombudsman & Communications kate.zerone@modivcare.com Amendola Communications Kim Warth kwarth@acmarketingpr.com

March 23, 2022 09:30 AM Eastern Daylight Time

SleepX applies to the Helsinki Committee for approval on its clinical trial with the SleepX PRO smartphone application

Appyea

SleepX, a subsidiary of AppYea (OTC: APYPD) focusing on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announces it has applied to the Helsinki Committee for approval to begin its planned clinical trial on the SleepX PRO application. This follows the company’s recent update that it intends to test the SleepX Pro application at a hospital sleep lab. The trial is the first step towards applying for an FDA approval under the first-of-its-kind medical device category for contactless detection of sleep apnea to be performed through the Artificial Intelligence (AI) analysis of breathing during sleep. As the request is submitted under a medical device category and the trial is touchless, the company expects the process to be quick and take up to a few months. SleepX Pro which is designed to diagnose sleep apnea using only a smartphone, requiring no physical contact with the subject. The global sleep apnea devices market size is valued at USD 3.7 billion as of 2020 with a 6.2% CAGR, reaching USD 6.1 billion by 2028, according to Grand View Research’s report. “Poor sleep is associated with the compromised immune system, heart problems, reduce physical and mental performance, mood problems, obesity and many other health problems”, said Neil Kline, Founder & former CEO of the American Sleep Association, and a SleepX Board Member. “Unfortunately, most people with sleep disorder breathing problems, like sleep apnea, are undiagnosed and untreated. Our goal in this unique technology is to raise the awareness to the problem and to improve people’s awareness that they can live healthier and more fulfilling lives.” “SleepX PRO makes for a unique, quick and friendly diagnosis tool that will prevent subjects from having to spend nights at sleep labs while saving the healthcare system and insurance companies hundreds of millions of dollars”, said Boris (Bary) Molchadsky, President and CEO of SleepX, and Chairman at AppYea. “We plan to make our diagnosis solution highly accessible, so people get tested easily. SleepX is an Israeli research and development company recently acquired by AppYea. The company had developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the company plans to start serial production in 2022. The company currently focuses its activities on the development and commercialization of its flagship product DreamIT. Legal Notice Regarding Forward-Looking Statements This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. APYP does not undertake any obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended. Contact Details Asaf Porat info@appyea.com Company Website http://www.appyea.com

March 23, 2022 07:53 AM Eastern Daylight Time

Centre for Neuro Skills California Facilities Awarded a Three-Year Accreditation by CARF International

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a premier provider of treatment for traumatic and acquired brain injury, announced that its California facilities have been accredited for a period of three years by CARF International (formerly Commission on Accreditation of Rehabilitation Facilities). CARF International is an independent, nonprofit accrediting body whose mission is to promote the quality, value and optimal outcomes of services through a consultative accreditation process and continuous improvement that centers on enhancing the lives of persons served. The accreditation extends through Dec. 31, 2024. CARF-accredited organizations identify leadership that embraces the values of accountability and responsibility while demonstrating corporate social responsibility. “What sets CNS apart from other rehabilitation facilities is our focus on brain injury and/or stroke, and individualized treatment for each patient, with the end goal of maximizing independence and quality of life,” said David Harrington, president and chief operating officer of CNS. “The CARF accreditation process is very rigorous, and the report truly captures the heart and culture of CNS – the dedication, inspiration, integrity and innovation toward our patients, their families, our colleagues, and the field of rehabilitation. CNS is honored by the high praise in the surveyors’ accreditation report.” During the rigorous on-site peer review process, CNS demonstrated to a team of surveyors its dedication and commitment to offering programs and services that are measurable, accountable and of the highest quality. Areas of strength noted include: CNS has an extraordinary discharge process with a level of detail and coordination throughout, incorporating all disciplines, resources, and coordination of appointments and ongoing areas of need in all California locations. All locations in California quickly adapted to the COVID-19 pandemic by utilizing telehealth and developing protocols consistent with government guidelines, with capacity for rapid testing on-site for both staff members and patients. CNS’ facilities are well designed, spacious and nicely furnished. At the clinics, patients are happy with the opportunities for rehabilitation, while those in the residential treatment enjoy desirable neighborhoods with easy access to shipping, restaurants, banking and public transportation. All the apartments are in a gated, secure community, with access to a pool and fitness center. The Bakersfield location was praised for its compassion and support for its clinician teams, who have demonstrated incredible longevity, dedication and compassion for the jobs that they do. Patients, family members and referral sources report a very high level of satisfaction with the quality and intensity of services in both the residential and outpatient settings. Their comments include: “It’s a good feeling in my heart when I refer to them,” “I would choose CNS for myself,” “They have changed my life,” and “No one else could do all of this for our family.” Programs awarded accreditation to CNS’ California facilities include: San Francisco Bay Area (Emeryville) Interdisciplinary Outpatient Medical Rehabilitation: Brain Injury Specialty Program (Adults) Interdisciplinary Outpatient Medical Rehabilitation: Brain Injury Specialty Program (Children and Adolescents) Interdisciplinary Outpatient Medical Rehabilitation: Stroke Specialty Program (Adults) Residential Rehabilitation: Brain Injury Specialty Program (Adults) Residential Rehabilitation: Stroke Specialty Program (Adults) Bakersfield Interdisciplinary Outpatient Medical Rehabilitation: Brain Injury Specialty Program (Adults) Interdisciplinary Outpatient Medical Rehabilitation: Brain Injury Specialty Program (Children and Adolescents) Interdisciplinary Outpatient Medical Rehabilitation: Stroke Specialty Program (Adults) Los Angeles Area (Woodland Hills) Residential Rehabilitation: Brain Injury Specialty Program (Adults) Residential Rehabilitation: Stroke Specialty Program (Adults) Los Angeles Area (Tarzana) Interdisciplinary Outpatient Medical Rehabilitation: Brain Injury Specialty Program (Adults) Interdisciplinary Outpatient Medical Rehabilitation: Brain Injury Specialty Program (Children and Adolescents) Interdisciplinary Outpatient Medical Rehabilitation: Stroke Specialty Program (Adults) About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. ### Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership, clinical staff or patients please contact Robin Carr at (415) 971-3991 or CNS@landispr.com. Contact Details Landis Communications Inc. Robin Carr +1 415-971-3991 cns@landispr.com Company Website https://www.neuroskills.com/

March 22, 2022 06:01 AM Pacific Daylight Time

SPARTA SCIENCE PARTNERS WITH INFLECT HEALTH TO REPLACE OUTDATED PHYSICIAN SCALES WITH AI-POWERED MOVEMENT HEALTH PLATFORM

Sparta Science

Sparta Science, an industry leader in movement health technology, has partnered with Inflect Health, the innovation hub of Vituity, to bring the Sparta Movement Health Platform to acute care clinics – and serve a chronic pain market forecast to reach $152 billion in this decade alone. Inflect will introduce Sparta Science’s innovative Movement Health Platform to seven of the innovation hubs’ clinics, replacing the outdated physician’s scale. Instead, a high-fidelity force plate collects individualized patient data through a simple, two-minute scan that generates over 3000 data points per second. The scans combine machine learning models and biomechanical analyses into a set of movement health metrics, movement qualities, and injury risk scores. “We are excited to begin this partnership with Inflect Health and we appreciate their investment in improving movement health for all individuals,” said Sparta Science CEO and founder Dr. Phil Wagner. “We are grateful to Inflect Health for recognizing the industry’s need to leverage advanced technologies using data science and AI to provide better personalized care.” Dr. Wagner, a physician and strength coach whose athletic career was cut short by a series of avoidable training injuries, originally led the development of the Movement Health Platform to help Navy SEALS and professional athletes. Sparta Science is now partnering with healthcare organizations to make this technology available to all patients. “As an industry, we’re only scratching the surface of what can be known about improving movement health,” said Andrew Smith, President of Inflect Health. “Through our partnership with Sparta Science and the help of the cutting-edge Sparta Movement Health Platform we look forward to serving key roles across the healthcare value spectrum, from diagnostic and preventative to rehabilitation and monitoring.” Formed by Vituity in December 2020, Inflect Health is a patient-centric healthcare innovation hub with access to 5,000 doctors and clinicians, 1,500 scribes, and over 300 hospitals, with frontline providers in some of the nation’s most acute care settings. Inflect Health capitalizes on its frontline care delivery experience, wide distribution channels, and access to small- to medium-sized enterprises across the entire healthcare space, to address local, community-based healthcare problems without the bureaucracy concerns that impede establishment healthcare organizations. ABOUT SPARTA SCIENCE: Sparta Science was founded with the vision that everybody should be able to move freely, without physical limitations, for as long as possible. Since bringing on our first customer in 2014, we’ve grown into a global full-stack movement health platform. Trusted by organizations spanning the healthcare, government, and sports industries, our platform empowers organizations to provide a better standard of care. Today, we’re ruthlessly focused on studying human movement and creating innovative ways to measure, monitor, and improve movement health. For more information, visit SpartaScience.com or follow us on Twitter and LinkedIn @SpartaScience. ABOUT INFLECT HEALTH: Inflect Health is a catalyst for better care. Headquartered in the San Francisco Bay Area with offices across America, Inflect Health provides guidance and financial support to early-stage healthcare and healthtech companies building promising solutions that offer to meet the needs of today’s evolving healthcare landscape. As the innovation hub of Vituity, a physician-owned multi-specialty partnership, Inflect Health has robust access to 5,000 doctors and clinicians, health systems, and other key industry players. This access allows Inflect Health to be a catalyst for consistent care improvement and innovative health technologies, by connecting innovators to capital, physicians, and patients in real-time. For more information on Inflect Health, including its portfolio, partners, services, and networking opportunities, visit www.InflectHealth.com or find Inflect Health on LinkedIn or Twitter @InflectHealth. ABOUT VITUITY: For 50 years, Vituity has been raising the standard of care and transforming how, when, and where care is delivered. As a physician-owned and -led multispecialty partnership, our 5,000 doctors and clinicians care for nearly 8 million patients annually across 450 practice locations and nine acute care specialties. Vituity’s patient focus and commitment to clinical excellence are the driving forces that place us at the heart of better care. Our front-line clinicians and business leaders develop healthcare solutions that improve outcomes for patients and hospitals. Our innovation hub, Inflect Health, identifies early-stage health-tech companies and facilitates a connection to physicians for testing, and our charitable foundation, Vituity Cares, extends our reach into communities that are most affected by healthcare disparities. Vituity is driven to continually transform healthcare through our collective passion for patients. Contact Details kglobal Jackie Hampton +1 443-814-0693 jacqueline.hampton@kglobal.com

March 22, 2022 09:00 AM Eastern Daylight Time

Roberts & Ryan Teams with Robert Irvine Supporting Our Nation's Veterans

Roberts & Ryan Investments, Inc.

Contact Details For Press Inquiries Please Contact Joe Pecoraro +1 917-658-8945 jpecoraro@roberts-ryan.com Company Website https://www.roberts-ryan.com

March 22, 2022 09:00 AM Eastern Daylight Time

Video

The Silent, Undetected Cause of Early Heart Disease

YourUpdateTV

One in 5 people worldwide have high Lipoprotein(a) – sometimes referred to as “L-P-little a” – an important genetic risk factor for premature heart disease and stroke. If you have a family history of early heart disease or have been told that heart disease “runs in your family,” but you’ve never been told why, it’s important to know if you have high Lp(a). Recently, founder and CEO Katherine Wilemon and chief medical officer Dr. Mary McGowan from the Family Heart Foundation, participated in a nationwide satellite media tour to discuss this silent, undetected cause of early heart disease. A video accompanying this announcement is available at: https://youtu.be/Tl08nDPSy9k Genetic disorders driving early cardiovascular disease are very common, but almost never diagnosed. Elevated levels of Lp(a) increase the risk of inflammation, blood clotting and clogging — or plaque buildup — inside your blood vessels, which can block the flow of blood and oxygen to your heart or brain and cause a heart attack or stroke. Almost everyone gets tested for high cholesterol, but in the U.S. fewer than 1% are screened for Lp(a). It’s important to know that Lp(a) levels are inherited — they’re unrelated to diet, exercise, obesity, and lifestyle. To find out if you’re affected, ask for a simple blood test to check your Lipoprotein(a). An Lp(a) test measures the level of Lipoprotein(a) in your blood. People might be surprised to know that this test is not part of a standard blood test that provides your cholesterol levels, so their doctor will need to order it directly. In order to create awareness worldwide of Lp(a), the Family Heart Foundation established the first annual Lp(a) Awareness Day on March 24. People can join the movement by following the Family Heart Foundation on Twitter, Facebook, and Instagram and sharing our messages about Lp(a) with friends and family. We aim to make a difference for those who have never heard of this common genetic condition. The Family Heart Foundation is addressing gaps in care through research, advocacy and awareness. The Family Heart Foundation aims to save generations of families from early heart disease by helping those at risk get the information they need to protect themselves and their family. For more information, visit MoreFamiliesMoreHearts.org About Katherine Wilemon: A decade ago, founder and CEO Katherine Wilemon created the Family Heart Foundation (formerly the FH Foundation) to improve early diagnosis and treatment of familial hypercholesterolemia (FH). Katherine had a heart attack at the age of 39, a diagnosis of familial hypercholesterolemia at 41, and, years later, she found out she also had elevated levels of lipoprotein(a). At the time of her diagnosis, Katherine realized that genetic disorders driving early cardiovascular disease were very common, but almost never diagnosed, leaving 9 out of those affected at high risk for the number one cause of death and illness. She resolved to bridge this enormous gap in diagnosis, because with early and accurate diagnosis, individuals can live decades longer without debilitating cardiovascular disease. She has led the Family Heart Foundation as it became a national catalyst for the research, education, awareness and support needed at every level of healthcare and public policy to prevent the early and devasting impact of genetic causes of heart disease and strokes including Familial Hypercholesterolemia (FH) and elevated Lipoprotein(a). Her vision and the mission of the Family Heart Foundation is to transform the lives of millions of families by assuring that everyone has the knowledge required to fight the early onset of heart attacks and strokes About Dr. Mary McGowan: Dr. Mary P. McGowan is the Chief Medical Officer of the Family Heart Foundation and the Co-Director of the Lipid Clinic at Dartmouth Hitchcock Heart and Vascular Center. Dr. McGowan received her medical degree from the University of Massachusetts and remained at the University of Massachusetts Medical Center for both internship and residency. She completed her fellowship at Johns Hopkins Hospital, and is the author of numerous articles and five books. She has been the principal investigator on more than 30 national and international clinical trials and has lectured widely in the United States, Canada, Europe, and Asia on cholesterol metabolism. Dr. McGowan has previously served on the alumni board at the University of Massachusetts Medical Center, the National Lipid Association Board of Directors and the NH Affiliate of the American Heart Association Board. Dr. McGowan lives in Bedford, NH with her husband, and they have three children. About the Family Heart Foundation: The Family Heart Foundation is a non-profit research and advocacy organization. The Foundation is a pioneer in the application of real-world evidence, patient-driven advocacy, and multi-stakeholder education to help prevent heart attacks and strokes caused by familial hypercholesterolemia and elevated lipoprotein(a), two common genetic disorders that have an impact across generations. The Family Heart Foundation conducts innovative research to break down barriers to diagnosis and management of inherited lipid disorders; educates patients, providers, and policy makers; advocates for change; and provides hope and support for families impacted by heart disease and stroke caused by FH, HoFH, and high Lp(a). The organization was founded in 2011 as the FH Foundation. For more information, visit FamilyHeart.org and follow us on Twitter, Facebook, Instagram and LinkedIn. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

March 17, 2022 04:00 PM Eastern Daylight Time

Video

Take Action for Heart Health

YourUpdateTV

Heart disease is responsible for over 600,000 deaths in the U.S. each year making it the leading (non-pandemic) cause of death in the U.S. Heart disease includes a number of different conditions that relate to your heart’s rhythm, muscle, and blood vessels. Luckily there are things we can all do to lower our risk for, or even prevent heart disease. Learning about what your genetics can tell you about your heart can be a good first step. Recently, Senior Product Scientist at 23andMe, Alisa Lehman, and Chief Clinical Officer at Lemonaid Health, Dr. Davis Liu, MD, participated in a nationwide satellite media tour to discuss how genetics can help people take a proactive approach to their health. A video accompanying this announcement is available at: https://youtu.be/213m-kngFRI When we look at the human genome, everyone is very similar. However, there are places in our DNA that are different from person to person, which are called genetic variants. Some of these variants are associated with certain health conditions. At 23andMe, scientists look at the variants you may have and can tell you if you may be genetically predisposed to developing conditions like type 2 diabetes, or migraine, or conditions related to heart disease. When it comes to heart disease, 23andMe’s personalized genetic reports can currently tell you if you're at an increased likelihood of developing conditions that affect your heart health, like high blood pressure, coronary artery disease, or high cholesterol. While genetics can give you a lot of insights about your likelihood of developing heart disease, there are many other factors that impact whether you actually go on to develop heart disease, and many of these factors are under your control, like your diet or exercise habits. Consult with your healthcare professional if you are concerned about your likelihood of developing heart disease, or if you have a personal or family history of heart disease. For more information, visit 23andMe.com About Alisa Lehman: Alisa is a Senior Product Scientist and has been working at 23andMe since 2015. Her team works to create scientifically accurate, consumer friendly genetic health features. Alisa holds a B.S. in Biology from MIT and a Ph.D. in Biological Sciences from Stanford University. About Davis Liu: Davis Liu, MD, is a board certified family doctor and Chief Clinical Officer at Lemonaid Health. Previously he worked at Kaiser Permanente in Roseville California for 15 years and lives in the Sacramento area with his wife and two teenagers. As the only doctor in his family, Dr. Liu feels compelled to make sure all Americans get the right health information to stay healthy and well. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

March 15, 2022 12:21 PM Eastern Daylight Time

Video

Bloom Healthcare Named a Direct Contracting Entity (DCE) by the Center for Medicare and Medicaid Innovation (Innovation Center)

Bloom Healthcare

Bloom Health Network, a wholly owned subsidiary of Bloom Healthcare Inc. (“Bloom Healthcare”) an industry leader in comprehensive home-based primary care and behavioral health integration, has been named a Direct Contracting Entity (DCE) by the Center for Medicare and Medicaid Innovation (Innovation Center). Bloom Healthcare began participating in the new Global and Professional Direct Contracting (“Direct Contracting”) model on January 1 st of this year and is one of eight (8) DCEs serving a High Need Population in the new model. High Needs Population DCEs use a model of care specifically designed to serve Medicare beneficiaries with complex medical needs, in particular those that are homebound or reside in assisted living facilities. The Direct Contracting model enables participating organizations, like Bloom Healthcare, to reduce medical expenditures and improve quality of care and health outcomes for Medicare beneficiaries with complex, chronic conditions and advanced stage illness. In addition, the model aims to improve how Medicare patients experience healthcare by reducing administrative burdens and increasing time spent with their primary healthcare provider. “Bloom Healthcare is redefining how our patients and partners experience healthcare by transforming the way care is delivered in the communities we serve. Our mission fully aligns with the goals and objectives of the Innovation Center’s Direct Contracting model and is yet another example of Bloom’s commitment to continuously innovate, improve quality of care and health outcomes for our patients” said Thomas Lally, M.D., CEO of Bloom Healthcare. Bloom Healthcare will be accountable for the cost and quality of services provided to their patients who are Medicare beneficiaries participating in the new model. The Direct Contracting model offers participating DCEs, like Bloom Healthcare, increased flexibilities, such as the ability to directly contract with other types of healthcare providers, develop preferred provider relationships and aligned incentives to improve care coordination. As a DCE, Bloom can offer benefit enhancements and additional services to eligible Medicare patients, which are not traditionally covered by the Medicare program. “Our participation in this new Innovation Center model will enable Bloom Healthcare and our participating primary care providers to provide their most vulnerable and medically complex patients with a level of value-based care that heretofore has not been possible in the traditional Medicare program. It builds on our organization’s success in other value-based care model partnerships, such as with Medicare Advantage organizations” said Franke P. Elliott, President of Bloom Health Network, Bloom Healthcare’s DCE. Bloom Healthcare enhances the quality of life and well-being of seniors and their caregivers by providing high quality healthcare wherever they choose to live – at home, or in senior housing, such as an assisted living facility. Patients are cared for by a primary care provider who is supported by a robust multidisciplinary care team, consisting of administrative coordinators, nurse clinical coordinators, social workers, pharmacists, behavioral health specialists and complex case managers, who provide care in accordance with a comprehensive care plan developed with patients and their families, with a focus on maximizing quality of life and meeting patients’ goals. For information about Bloom Healthcare and our participation in the Direct Contracting model, please visit https://bloomhealthcare.com/bloom-dce/ Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document. Contact Details Angela Fulcher +1 512-470-1970 afulcher@growthstrategy.ai

March 15, 2022 08:40 AM Mountain Daylight Time

Image

4D Path, PathPresenter Announce Partnership to Advance AI-enabled Digital Pathology for End-to-End Breast Tumor Profiling

4D Path

PathPresenter, a pioneer in the development of digital pathology software, and 4D Path Inc., developer of a pan-cancer diagnostic and precision oncology platform enabling AI-based biomarker typing and prognostication from H&E images, are announcing today a global partnership to distribute 4D Q-plasia OncoReader Breast within PathPresenter’s new Clinical Workflow Platform, ClinPx. 4D Q-plasia OncoReader Breast provides histopathologists with an adjunct technology to potentially improve diagnostic accuracy of breast cancer features (e.g., its invasiveness, grades, ki-67 status, etc.) solely from digitized histopathology images obtained via biopsies or resections. Through this partnership, pathologists will have the ability to run the 4D Q-Plasia OncoReader Breast directly within the ClinPx whole slide image viewer. Embedding this AI technology within PathPresenter’s emerging ClinPx platform – a scanner-agnostic digital pathology workflow solution – could accelerate the adoption of AI tools within clinical workflows. “We believe that the integration of these two technologies will redefine how AI can be adopted by everyday pathologists,” said Rajendra Singh, M.D., Founder of PathPresenter. The primary purpose of integrating 4D’s proprietary algorithms within the ClinPx platform is to potentially improve the throughput, reliability, and quality of consultations provided by physicians. Additionally, users from pharmaceutical organizations could also benefit from the enablement of the standardized central pathology review of certain biomarkers within the context of clinical trials leveraging the ClinPx platform. “This unique partnership is very much needed to make the most of the increasing investment in digital pathology,” said Tathagata Dasgupta, Founder and President of 4D Path. “While PathPresenter offers a software platform made by pathologists to serve pathologists in their digital workflow, it will have at its heart the 4D Path-driven end-to-end tumor profiling white-box solution that can produce synoptic reports to potentially assist clinical reporting.” To advance the adoption of digital pathology worldwide, 4D Path and PathPresenter have created exclusive educational content to teach current and future pathologists about how evaluation of breast cancer features prior to downstream genomic and molecular testing can potentially improve patient care. This information will be available to PathPresenter’s 40,000 global users at PathPresenter.net. *4D Q-plasia OncoReader Breast has not been approved by the FDA or the EMA for primary diagnosis. 4D Q-plasia OncoReader Breast is for Research Use Only (RUO) About PathPresenter PathPresenter has been a pioneer in the development of digital pathology software since 2017. Originally known for its education platform, PathPresenter has evolved into a suite of interconnected digital pathology products that enable the use of digital pathology images for clinical care, medical education, and research. With over 40,000 registered users adopting its technologies around the world, PathPresenter enables a global clinical and data network for AI-driven precision medicine to define a new standard of care. Visit https://pathpresenter.net/ to learn more. About 4D Path 4D Path’s mission is to democratize precision diagnostics and oncology by unveiling previously hidden information purely from cellular snapshots of tissue ( e.g., histology) or liquid ( e.g., cytology) without the use of antibody stains. The company’s cloud-based 4D Q-Plasia OncoReader (QPOR) is a U.S. patented pan-cancer precision diagnostic and oncology platform which is being designed to extract diagnostic data from routine cytology and histology images. Its beachhead product, the 4D QPOR Breast, has been awarded FDA Breakthrough Device Designation for potentially improving diagnostic accuracy over the current standard of care. This end-to-end solution provides an adjunct tool, which aims to accelerate diagnostic turnaround times, reduce cost, and improve diagnostic accuracy in a single step. In addition, this technology is being designed to identify an overall biologic cancer signature to guide therapeutic management from as early as pre-treatment biopsy/resection specimens. This single test will not require the multiple additive signatures that multi-omics platforms depend upon, with their additional burdens of cost, diagnostic delay, and reliance on specialized equipment. This approach toward tumor profiling could lead to the 4D QPOR becoming an efficient and universally accessible platform to better predict and stratify patient response to therapy. The platform can integrate seamlessly into any existing clinical workflow without altering current practices. Visit https://4dpath.com to learn more. Contact Details SVM Public Relations & Marketing Communications Jordan Bouclin +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://4dpath.com/

March 15, 2022 10:00 AM Eastern Daylight Time

1 ... 189 190 191 192 193 ... 247